Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
M. Kim
Institution:
UCB Pharma (United States)
Observed institution:
UCB Pharma (United States)
OpenAlex ID:
A5108211641
Pos0247 Resolution of Enthesitis and Peripheral Arthritis With Bimekizumab in Patients With Axial Spodyloarthritis: Week 52 Results From the Be Mobile 1 and Be Mobile 2 Phase 3 Studies
2023
·
S. Ramiro
, D. Poddubnyy
, et al.
·
Annals of the Rheumatic Diseases
·
1
PDF
Pos0683 an Exploratory Analysis of the Potential Disconnect Between Objective Inflammatory Response and Clinical Response Following Certolizumab Pegol Treatment in Patients With Active Axial Spondyloarthritis
2023
·
M. Rudwaleit
, F. Van den Bosch
, et al.
·
Annals of the Rheumatic Diseases
·
1
PDF
Résolution des enthésites et des arthrites périphériques avec le bimékizumab chez les patients atteints de spondyloarthrite axiale : résultats à la semaine 52 des études de phase III BE MOBILE 1 et BE MOBILE 2
2023
·
M. Dougados
, S. Ramiro
, et al.
·
Revue du Rhumatisme
Pos0679 Comparison of Established and New, Preliminary Proposed Asas Cut-offs for Inflammatory Mri Lesions in the Sacroiliac Joints of Axial Spondyloarthritis Patients and Implications for Recruitment in Clinical Studies
2023
·
X. Baraliakos
, P. Machado
, et al.
·
Annals of the Rheumatic Diseases
PDF
Comparaison des nouveaux seuils à ceux préalablement proposés par la société ASAS pour les lésions inflammatoires des articulations sacro-iliaques à l’IRM de la spondylarthrite axiale et implications pour le recrutement dans les études cliniques
2022
·
M. Dougados
, X. Baraliakos
, et al.
·
Revue du Rhumatisme
Pos0941 Long-term Clinical Outcomes of Certolizumab Pegol Treatment in Patients With Active Non‑radiographic Axial Spondyloarthritis Stratified by Baseline Mri and C-reactive Protein Status
2022
·
P. Robinson
, W.P. Maksymowych
, et al.
·
Annals of the Rheumatic Diseases
PDF
Show more works
View as search
Works count:
6
Citation count:
2
H-index:
1
I10-index:
Year
Topic
Type